|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aims were to compare methotrexate and tumor necrosis factor inhibitor (TNFi) persistence in spondyloarthritis vs. RA and to determine whether concomitant conventional synthetic DMARD (csDMARD) use is associated with improved TNFi persistence in spondyloarthritis.
|
31474599 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.
|
31326602 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pioneering studies have revealed the presence of a TNF-dependent proinflammatory cytokine cascade in several IMIDs, and the introduction of anti-TNF therapy 20 years ago has proven effective to reduce inflammation and clinical symptoms in RA, SpA, and other IMID, providing unprecedented clinical benefits and a valid alternative in case of failure or intolerable adverse effects of conventional disease-modifying antirheumatic drugs (DMARDs, for RA) or non-steroidal anti-inflammatory drugs (NSAIDs, for SpA).
|
30941119 |
2019 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the incidence of serious infections (SIs) among the spondyloarthropathy (SpA) patients from the "Gruppo Italiano per lo Studio delle Early Arthritis" (GISEA) registry and treated with tumour necrosis factor (TNF) inhibitors (TNFIs), and to identify the factors associated with the development of the infections.
|
30767865 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis (SpA), a chronic inflammatory, rheumatic disease, and hidradenitis suppurativa (HS), a chronic, debilitating, inflammatory skin disease, share several clinical and pathophysiological features, such as the association with inflammatory bowel disease and elevated cytokine levels IL-17 and TNF-α.
|
29751976 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of tumor necrosis factor (TNF) and IL-17A on osteogenesis was tested in an osteoblastic differentiation assay using SpA fibroblast-like synoviocytes (FLS) differentiated with dexamethasone, β-glycophosphatase, and ascorbic acid.
|
30390386 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF blockade showed efficacy in peripheral SpA, and other targets (IL-17 and IL-23) should be investigated in clinical trials.
|
31302784 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry.
|
29517554 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive clinical-genetic model of long-term non-response to tumor necrosis factor-alpha inhibitor therapy in spondyloarthritis.
|
31119895 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Spondyloarthritis (SpA) and inflammatory bowel diseases (IBD) are chronic inflammatory diseases characterized by an aberrant immune response and inflammation with a key role for TNF in their pathogenesis.
|
30745872 |
2019 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pubmed search retained 15 publications in spondyloarthritis, 12 with corticosteroids (total of 468 injections in 268 patients), including 2 small-sized controlled studies, and 3 with TNF blockers (24 patients in open studies).
|
31216488 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The development of anti-drug antibodies against tumor necrosis factor inhibitors is a likely explanation for the failure of TNF-inhibitors in patients with spondyloarthritis.
|
28743358 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of tumor necrosis factor-alpha (TNF-α)-targeting drugs has given new opportunities in the treatment of various inflammatory rheumatic diseases and has been the most important development in the treatment of spondyloarthritis (SpA).
|
30673815 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the level of serum Dkk-1 by TNF inhibitors may be the molecular basis for inhibiting the formation of new bone in SpA patients.
|
30206711 |
2019 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients fulfilling the Assessment in SpondyloArthritis international Society classification criteria for axial spondyloarthritis in the Swiss Clinical Quality Management cohort were included in this study if a first TNF inhibitor on standard dosage was started after recruitment and if a baseline visit was available.
|
31145730 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor treatment increases both the Th17 and Th22 T helper subsets in spondyloarthritis.
|
31512766 |
2019 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine the pregnancy achievement and outcomes in couples in which men with spondyloarthritis (SpA) were exposed to tumor necrosis factor inhibitors (TNFi).
|
30824658 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNFα) has an important role in the body composition of patients with rheumatoid arthritis (RA), Crohn's disease (CD), and spondyloarthritis (SpA).
|
29600354 |
2019 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical improvement in joint counts was associated with a histologic decrease in synovial sublining macrophages (P = 0.028) and neutrophils (P = 0.004), both of which are sensitive synovial biomarkers of inflammatory response in peripheral SpA, as well as with decreased synovial expression of IL-17A messenger RNA (mRNA) (P = 0.010) but not of tumor necrosis factor mRNA.
|
29869838 |
2018 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical response to anti-TNF was defined according to a ⩾ 20% improvement in Assessment of SpondyloArthritis international Society criteria at 24 weeks.
|
29329443 |
2018 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.
|
28893679 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only the TNFA -1031T>C was singly associated with SpA, and the haplotype C/G, resulting from -1031T>C/-308G>A combination, was significantly associated with a reduced risk of SpA (OR: 0.67, CI: 0.46-0.97; p = 0.035).
|
29579081 |
2018 |
|
Spondylarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
|
29606666 |
2018 |
|
Spondylarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD4 T cells in 98 blood samples of patients with RA (n = 78) or SpA (n = 20) were quantified by flow cytometry after stimulation with VZV antigen and the polyclonal stimulus Staphylococcus aureus enterotoxin B (SEB), and they were characterized for expression of cytokines (interferon-γ, tumor necrosis factor [TNF]-α, interleukin [IL]-2) and markers for activation (CD69), differentiation (CD127), or functional anergy programmed death 1 molecule [PD-1], cytotoxic T-lymphocyte antigen 4 [CTLA-4].
|
30413189 |
2018 |
|
Spondylarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of imaging in the diagnosis, management, and follow-up of patients with SpA has become dramatically more important with the introduction of new therapies such as tumor necrosis factor-α inhibitors.
|
29672807 |
2018 |